Supernus Pharmaceuticals Management

Management criteria checks 2/4

Supernus Pharmaceuticals' CEO is Jack Khattar, appointed in Jan 2005, has a tenure of 19.25 years. total yearly compensation is $10.01M, comprised of 9.1% salary and 90.9% bonuses, including company stock and options. directly owns 3.54% of the company’s shares, worth €53.09M. The average tenure of the management team and the board of directors is 8.8 years and 13.3 years respectively.

Key information

Jack Khattar

Chief executive officer

US$10.0m

Total compensation

CEO salary percentage	9.1%
CEO tenure	19.3yrs
CEO ownership	3.5%
Management average tenure	8.8yrs
Board average tenure	13.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jack Khattar's remuneration changed compared to Supernus Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	US$1m
Sep 30 2023	n/a	n/a	US$26m
Jun 30 2023	n/a	n/a	US$43m
Mar 31 2023	n/a	n/a	US$52m
Dec 31 2022	US$10m	US$914k	US$61m
Sep 30 2022	n/a	n/a	US$38m
Jun 30 2022	n/a	n/a	US$57m
Mar 31 2022	n/a	n/a	US$73m
Dec 31 2021	US$8m	US$870k	US$53m
Sep 30 2021	n/a	n/a	US$82m
Jun 30 2021	n/a	n/a	US$100m
Mar 31 2021	n/a	n/a	US$111m
Dec 31 2020	US$7m	US$836k	US$127m
Sep 30 2020	n/a	n/a	US$129m
Jun 30 2020	n/a	n/a	US$118m
Mar 31 2020	n/a	n/a	US$116m
Dec 31 2019	US$8m	US$812k	US$113m
Sep 30 2019	n/a	n/a	US$106m
Jun 30 2019	n/a	n/a	US$105m
Mar 31 2019	n/a	n/a	US$103m
Dec 31 2018	US$7m	US$724k	US$111m
Sep 30 2018	n/a	n/a	US$99m
Jun 30 2018	n/a	n/a	US$87m
Mar 31 2018	n/a	n/a	US$73m
Dec 31 2017	US$6m	US$614k	US$57m

Compensation vs Market: Jack's total compensation ($USD10.01M) is above average for companies of similar size in the German market ($USD1.61M).

Compensation vs Earnings: Jack's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Jack Khattar (62 yo)

19.3yrs

Tenure

US$10,012,717

Compensation

Mr. Jack A. Khattar founded Supernus Pharmaceuticals, Inc. (Formerly, Shire Laboratories, Inc.) in 2005 and has served as Chief Executive Officer, President, Secretary and Director since 2005. He serves as...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jack Khattar	Founder	19.3yrs	US$10.01m	3.54% $ 53.1m
Timothy Dec	Senior VP & CFO	2.7yrs	US$1.26m	0.013% $ 197.1k
Padmanabh Bhatt	Chief Scientific Officer & Senior VP of Intellectual Property	12.1yrs	US$1.12m	0.016% $ 234.9k
Frank Mottola	Senior Vice President of Quality	4.3yrs	US$1.02m	0.014% $ 213.1k
Jonathan Rubin	Senior VP of Research & Development and Chief Medical Officer	4.2yrs	US$1.25m	0.0085% $ 127.2k
Kevin Anderson	Compliance Officer	12.3yrs	no data	no data
Todd Horich	Senior Vice President of Marketing & Market Access	9.3yrs	no data	no data
Taylor Raiford	Senior Vice President of Sales	9.3yrs	no data	no data
Bryan Roecklein	Senior Vice President of Corporate Development	8.8yrs	no data	no data
Tami Martin	Senior Vice President of Regulatory Affairs	8.3yrs	US$843.16k	0.16% $ 2.4m
Jeff Bozick	Senior Vice President of Supply Chain	2.9yrs	no data	no data

8.8yrs

Average Tenure

62yo

Average Age

Experienced Management: S49's management team is seasoned and experienced (8.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jack Khattar	Founder	19.3yrs	US$10.01m	3.54% $ 53.1m
Charles Newhall	Independent Chairman of the Board	19.3yrs	US$356.54k	0.22% $ 3.3m
John Siebert	Independent Director	13.3yrs	US$338.04k	0.16% $ 2.4m
Georges Gemayel	Independent Director	9.1yrs	US$323.04k	0.031% $ 471.4k
Carrolee Barlow	Independent Director	5.8yrs	US$305.54k	0.031% $ 471.4k
Frederick Hudson	Independent Director	14.3yrs	US$340.54k	0.068% $ 1.0m
Bethany Sensenig	Independent Director	less than a year	no data	no data

13.3yrs

Average Tenure

63yo

Average Age

Experienced Board: S49's board of directors are seasoned and experienced ( 13.3 years average tenure).

Supernus Pharmaceuticals Management

Management criteria checks 2/4

Key information

Recent management updates

Supernus Pharmaceuticals, Inc. Appoints Bethany L. Sensenig to Board of Directors

Senior Vice President of Quality recently sold €160k worth of stock

Insufficient new directors

Insufficient new directors

Supernus Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2022

Supernus Pharmaceuticals, Inc. Announces Executive Changes

Recent updates

Supernus Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023

Full year 2023 earnings released: EPS: US$0.024 (vs US$1.13 in FY 2022)

Supernus Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024

New minor risk - Insider selling

Investor sentiment improves as stock rises 15%

Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.29 loss per share (vs US$0.033 profit in 3Q 2022)

Supernus Pharmaceuticals, Inc. Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

Supernus Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Supernus Pharmaceuticals, Inc. Resubmits NDA for SPN-830 Apomorphine Infusion Device

Supernus Pharmaceuticals, Inc. Announces New Qelbree®? Data Showing Improvement in ADHD Symptoms

Supernus Pharmaceuticals, Inc. Appoints Bethany L. Sensenig to Board of Directors

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.015 loss per share (vs US$0.15 profit in 2Q 2022)

Supernus Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2023

Supernus Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) dropped from Russell 2000 Value-Defensive Index

First quarter 2023 earnings released: EPS: US$0.31 (vs US$0.48 in 1Q 2022)

Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023

Senior Vice President of Quality recently sold €160k worth of stock

Full year 2022 earnings released: EPS: US$1.13 (vs US$1.01 in FY 2021)

Supernus Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Insufficient new directors

Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2022

Supernus Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Supernus Pharmaceuticals, Inc. Provides Regulatory Update on SPN-830

Insufficient new directors

Supernus Pharmaceuticals, Inc. Provides Earning Guidance for Full Year 2022

Supernus Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Supernus Pharmaceuticals, Inc. announced delayed 10-Q filing

Supernus Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2022

Supernus Pharmaceuticals, Inc. Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults

Supernus Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Year 2022

Supernus Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year of 2022

Supernus Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Supernus Pharmaceuticals, Inc. Resubmits NDA for SPN-830 Apomorphine Infusion Device

Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN) completed the acquisition of Adamas Pharmaceuticals, Inc. (NasdaqGM:ADMS) from Mohr Davidow Ventures and others.

Third quarter 2021 earnings released: EPS US$0.41 (vs US$0.76 in 3Q 2020)

Investor sentiment improved over the past week

Supernus Pharmaceuticals, Inc. Announces Qelbree sNDA for Adult Indication Accepted for Review by FDA

Supernus Pharmaceuticals, Inc. Reiterates Financial Guidance for Full Year 2021

Second quarter 2021 earnings released: EPS US$0.45 (vs US$0.66 in 2Q 2020)

Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) dropped from Russell 3000 Growth Index

Supernus Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Treatment Qelbree for the Treatment of Attention-Deficit Hyperactivity Disorder in Pediatric Patients

Supernus Pharmaceuticals, Inc. Reiterates Full Year 2021 Financial Guidance

Supernus Pharmaceuticals, Inc. announced delayed annual 10-K filing

Full year 2020 earnings released: EPS US$2.41 (vs US$2.16 in FY 2019)

Revenue misses expectations

Supernus Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Supernus Receives FDA Notice Assigning Early April 2021 PDUFA Date for SPN-812 NDA

Supernus Pharmaceuticals, Inc. Resubmits New Drug Application for SPN-812 for the Treatment of ADHD in Pediatric Patients

New 90-day high: €24.80

Investor sentiment improved over the past week

New 90-day high: €21.80

Supernus Announces Positive Results from Phase III Study for SPN-812 in Adults with ADHD

New 90-day high: €21.60

Investor sentiment improved over the past week

Supernus Pharmaceuticals, Inc. Announces Executive Changes

Supernus Pharmaceuticals, Inc. Provides Regulatory Updates for SPN-812 and SPN-830

Revenue beats expectations

Third quarter 2020 earnings released: EPS US$0.76

Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2020

Supernus Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 03, 2020

Supernus Pharmaceuticals, Inc. Announces Executive Changes

Supernus Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 18, 2020

Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN) acquired USWM Enterprises, LLC from US WorldMeds, LLC.

CEO Compensation Analysis

CEO